EP 4018999 A1 20220629 - DERMAL FILLER COMPOSITIONS INCLUDING ANTIOXIDANTS
Title (en)
DERMAL FILLER COMPOSITIONS INCLUDING ANTIOXIDANTS
Title (de)
DERMALE FÜLLSTOFFZUSAMMENSETZUNGEN MIT ANTIOXIDANTIEN
Title (fr)
COMPOSITIONS DE REMPLISSAGE DERMIQUE COMPRENANT DES ANTIOXYDANTS
Publication
Application
Priority
- US 201161493309 P 20110603
- EP 19166794 A 20120601
- EP 12726327 A 20120601
- US 2012040459 W 20120601
Abstract (en)
The invention provides a method of making a dermal filler comprising the steps of providing hyaluronic acid; reacting a crosslinking agent with a Vitamin C derivative; adding the reacted crosslinking agent and Vitamin C derivative to the hyaluronic acid to form a crosslinked hyaluronic acid composition; and homogenizing and neutralizing the crosslinked hyaluronic acid composition to obtain an injectable gel.
IPC 8 full level
A61K 8/73 (2006.01); A61K 8/04 (2006.01); A61K 8/67 (2006.01); A61K 47/60 (2017.01); A61K 47/61 (2017.01); A61L 27/20 (2006.01); A61P 3/02 (2006.01); A61P 17/00 (2006.01); A61P 17/02 (2006.01); A61P 43/00 (2006.01); A61Q 19/08 (2006.01); C08B 37/08 (2006.01)
CPC (source: CN EP KR RU US)
A61K 8/042 (2013.01 - CN EP KR US); A61K 8/676 (2013.01 - CN EP KR RU US); A61K 8/735 (2013.01 - CN EP KR RU US); A61K 9/0024 (2013.01 - KR); A61K 9/06 (2013.01 - KR); A61K 31/375 (2013.01 - KR); A61K 47/60 (2017.07 - EP US); A61K 47/61 (2017.07 - EP KR US); A61L 27/00 (2013.01 - US); A61L 27/20 (2013.01 - US); A61L 27/50 (2013.01 - US); A61L 27/52 (2013.01 - US); A61L 27/54 (2013.01 - US); A61L 27/58 (2013.01 - US); A61P 3/02 (2017.12 - EP); A61P 17/00 (2017.12 - EP KR); A61P 17/02 (2017.12 - EP); A61P 43/00 (2017.12 - EP); A61Q 19/00 (2013.01 - RU); A61Q 19/08 (2013.01 - CN EP KR RU US); C08B 37/0072 (2013.01 - US); C08J 3/075 (2013.01 - RU); A61K 2800/91 (2013.01 - CN EP KR US); A61L 2300/204 (2013.01 - US); A61L 2300/402 (2013.01 - US); A61L 2400/06 (2013.01 - KR US)
Citation (applicant)
- US 2003148995 A1 20030807 - PIRON ESTELLE [FR], et al
- US 2008089918 A1 20080417 - LEBRETON PIERRE [FR]
- US 2010028438 A1 20100204 - LEBRETON PIERRE F [FR]
- US 2006194758 A1 20060831 - LEBRETON PIERRE [FR]
- WO 2004073759 A1 20040902 - AVENTIS PHARMACEUTICALS HOLDIN [US], et al
- US 91046610 A 20101022
- FALCONE ET AL.: "Temporary Polysaccharide Dermal Fillers: A Model for Persistence Based on Physical Properties", DERMATOL SURG, vol. 35, no. 8, 2009, pages 1238 - 1243, XP055123083, DOI: 10.1111/j.1524-4725.2009.01218.x
- "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT WILLIAMS & WILKINS PUBLISHERS
- "Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT, WILLIAMS & WILKINS
- "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 2001, MCGRAW-HILL PROFESSIONAL
- "Handbook of Pharmaceutical Excipients", 2003, APHA PUBLICATIONS
Citation (search report)
- [A] US 2009143331 A1 20090604 - STROUMPOULIS DIMITRIOS [US], et al
- [A] US 2009017091 A1 20090115 - DANILOFF GEORGE Y [US], et al
- [A] EP 1932530 A1 20080618 - HAYASHIBARA BIOCHEM LAB [JP]
- [A] US 5690961 A 19971125 - NGUYEN TUYEN T [US]
- [A] PARK, D.J. ET AL.: "IN VITRO EVALUATION OF CONJUGATED HYALURONIC ACID WITH ASCORBIC ACID", 2010, XP002706399, Retrieved from the Internet <URL:http://www.bjjprocs.boneandjoint.org.uk/content/92-B/SUPP_I/115.3.abstract> [retrieved on 20130729]
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2012167079 A2 20121206; WO 2012167079 A3 20131024; AU 2012262047 A1 20140116; AU 2016201862 A1 20160421; AU 2016201862 B2 20171109; CA 2838237 A1 20121206; CA 2838237 C 20200526; CA 3038735 A1 20121206; CA 3038735 C 20211123; CA 3133676 A1 20121206; CN 103702659 A 20140402; CN 103702659 B 20161221; CN 107412002 A 20171201; EP 2714002 A2 20140409; EP 2714002 B1 20190403; EP 3536307 A1 20190911; EP 3536307 B1 20211020; EP 4018999 A1 20220629; ES 2738208 T3 20200120; JP 2014515307 A 20140630; JP 2017008097 A 20170112; JP 2017217500 A 20171214; JP 2019069238 A 20190509; JP 2020179280 A 20201105; JP 6009550 B2 20161019; JP 6195963 B2 20170913; JP 6463427 B2 20190206; JP 6749993 B2 20200902; JP 6995946 B2 20220117; KR 102015676 B1 20191021; KR 102154944 B1 20200911; KR 102238406 B1 20210408; KR 102312056 B1 20211012; KR 20140072008 A 20140612; KR 20190100979 A 20190829; KR 20200106224 A 20200911; KR 20210040466 A 20210413; NZ 618587 A 20160429; RU 2013158448 A 20150720; RU 2017122340 A 20181226; RU 2017122340 A3 20200717; RU 2624239 C2 20170703; RU 2740454 C2 20210114; US 10624988 B2 20200421; US 2013123210 A1 20130516; US 2015352251 A1 20151210; US 2017136145 A1 20170518; US 2020139006 A1 20200507; US 2023310700 A1 20231005; US 9149422 B2 20151006; US 9737633 B2 20170822
DOCDB simple family (application)
US 2012040459 W 20120601; AU 2012262047 A 20120601; AU 2016201862 A 20160324; CA 2838237 A 20120601; CA 3038735 A 20120601; CA 3133676 A 20120601; CN 201280036621 A 20120601; CN 201611139201 A 20120601; EP 12726327 A 20120601; EP 19166794 A 20120601; EP 21203127 A 20120601; ES 12726327 T 20120601; JP 2014513745 A 20120601; JP 2016179330 A 20160914; JP 2017157047 A 20170816; JP 2018247976 A 20181228; JP 2020136201 A 20200812; KR 20147000002 A 20120601; KR 20197024533 A 20120601; KR 20207025510 A 20120601; KR 20217009866 A 20120601; NZ 61858712 A 20120601; RU 2013158448 A 20120601; RU 2017122340 A 20170601; US 201213486754 A 20120601; US 201514829201 A 20150818; US 201715419542 A 20170130; US 202016735532 A 20200106; US 202217985771 A 20221111